TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22542356

Group type: EXPERIMENTAL
Intervention: Group I (anterior/apical with or without posterior repairs)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Groups I-III (concomitant surgeries)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Group III (nonprolapse procedures)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Groups I and II (anterior/apical repairs and posterior repairs)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Group IV (no concomitant surgeries)
Number of subjects: 597
Study: 20418251

Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation (n=95)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Supportive listening (n=101)
Number of subjects: 296

Group type: COMPARATOR
Intervention: General practitioner treatment as usual (n=100)
Number of subjects: 296
Study: 17934448

Group type: EXPERIMENTAL
Intervention: Peptide YY3-36 (PYY) at high plasma concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low levels of PYY
Number of subjects: 0
Study: 16041731

Group type: EXPERIMENTAL
Intervention: Phytotherapeutic agent (PA) - Matricariae recutita, Foeniculum vulgare and Melissa officinalis, administered twice a day for 1 week.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo, administered twice a day for 1 week.
Number of subjects: 93
Study: 12466166

Group type: EXPERIMENTAL
Intervention: Clear corneal phacoemulsification and implantation of a foldable intraocular lens
Number of subjects: 47
Study: 10027360

Group type: EXPERIMENTAL
Intervention: Quantitative tests for small fibre neuropathy in patients with STC
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Quantitative tests for axon-reflex sweating in patients with STC
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Quantitative tests for sensory fibre dysfunction in patients with STC
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison with matched control subjects
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison with diabetic patients with gastrointestinal symptoms
Number of subjects: 33
Study: 8749724

Group type: EXPERIMENTAL
Intervention: Neurobehavioral treatment with adjunct therapies (acupuncture, anticraving medication, brainwave therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard treatment sessions attended
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunct therapies (acupuncture, anticraving medication, brainwave therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurobehavioral treatment alone
Number of subjects: 0
Study: 2201988

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyroxine (T4) for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T3 and T4
Number of subjects: 0
Study: 7389385

Group type: EXPERIMENTAL
Intervention: 50 mg diacetylrhein per day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30908361

Group type: EXPERIMENTAL
Intervention: TCA→FRF
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: FRF→TCA
Number of subjects: 67

Group type: COMPARATOR
Intervention: FRF
Number of subjects: 67

Group type: COMPARATOR
Intervention: TCA20%
Number of subjects: 67
Study: 27937053

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg single oral dose
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Ticagrelor 50 μM incubation
Number of subjects: 196
Study: 26310692

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once-weekly
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study: 24530652

Group type: EXPERIMENTAL
Intervention: Single dose testosterone administration
Number of subjects: 0
Study: 22954906

Group type: EXPERIMENTAL
Intervention: Sparse decoding algorithm for neuronal activity
Number of subjects: 23

Group type: COMPARATOR
Intervention: Existing methods for decoding neuronal activity
Number of subjects: 23
Study: 19237980

Group type: EXPERIMENTAL
Intervention: CSL 10 ml/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CSL 30 ml/kg
Number of subjects: 100
Study: 17879563

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15006108

Group type: EXPERIMENTAL
Intervention: Faecal occult blood (FOB) screening
Number of subjects: 153000

Group type: COMPARATOR
Intervention: Symptomatic presentation (Control)
Number of subjects: 153000
Study: 12439474

Group type: EXPERIMENTAL
Intervention: Functional appliances
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 6
Study: 9821904

Group type: EXPERIMENTAL
Intervention: General physical training program (twice a week for 3 months, including group training and a daily home exercise program)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: General physical training program
Number of subjects: 25
Study: 7867678

Group type: EXPERIMENTAL
Intervention: mizolastine 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: mizolastine 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: mizolastine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: mizolastine 5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: clemastine 2 mg
Number of subjects: 24
Study: 2572902

Group type: EXPERIMENTAL
Intervention: 30 mg pamidronate as a single intravenous infusion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 600 mg clodronate as a single intravenous infusion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etidronate as three infusions of 7.5 mg/kg per day for three consecutive days
Number of subjects: 48
Study: 792994

Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline inhaled via IPPB
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline inhaled via IPPB
Number of subjects: 12
Study: 31823444

Group type: EXPERIMENTAL
Intervention: Lurasidone (40 or 80 mg/day)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Risperidone (2, 4 or 6 mg/day)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 384
Study: 30771686

Group type: EXPERIMENTAL
Intervention: Fish oil (4.4 g/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27306854

Group type: EXPERIMENTAL
Intervention: Delirium care
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study: 25822197

Group type: EXPERIMENTAL
Intervention: Dynamic orthosis (vacuum-fit flexible but blocked orthosis)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dorsal plaster splint
Number of subjects: 29
Study: 22984950

Group type: EXPERIMENTAL
Intervention: Verbal time estimates in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TBPM task without external clock in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TBPM task with access to a clock in Experiment 2
Number of subjects: 0
Study: 21419297

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI) followed by a final rinse with 0.2% chlorhexidine (CHX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hedström filing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemomechanical preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final rinse with CHX after PUI
Number of subjects: 0
Study: 19289928

Group type: EXPERIMENTAL
Intervention: Tailored newsletters
Number of subjects: 225

Group type: COMPARATOR
Intervention: Generic newsletters
Number of subjects: 225
Study: 17353334

Group type: EXPERIMENTAL
Intervention: High creatine intake with diet restrictions to reduce guanidinoacetate synthesis in GAMT‐d patients.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Different creatine intakes in AGAT‐d patients.
Number of subjects: 5
Study: 15347339

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (three times weekly)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (five times weekly)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 55
Study: 11493504

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 50% nitrous oxide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sevoflurane with oxygen only (control)
Number of subjects: 64
Study: 9568413

Group type: EXPERIMENTAL
Intervention: Neoral at 2.5 mg/kg/day or equivalent to pre-conversion SIM dosage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sandimmun (SIM)
Number of subjects: 58
Study: 8929936

Group type: EXPERIMENTAL
Intervention: Social model residential program providing integrated mental health and substance abuse treatment
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Community‐based nonresidential program using the same social model approach
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group receiving no intervention but free to access other community services
Number of subjects: 276
Study: 2198731

Group type: EXPERIMENTAL
Intervention: Enalapril (mean dosage 25 +/- 10 mg/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Captopril (mean dosage 77 +/- 26 mg/day)
Number of subjects: 29
Study: 403149

Group type: EXPERIMENTAL
Intervention: Oral administration of tritium-labeled ergot alkaloids
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous administration of tritium-labeled ergot alkaloids
Number of subjects: 6
Study: 29736892

Group type: EXPERIMENTAL
Intervention: Pittsburgh Fatigability Scale (PFS)
Number of subjects: 79
Study: 27583439

Group type: EXPERIMENTAL
Intervention: Lipid solutions delivered separately (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lipid solutions in mixture with TPN solutions (Group 2)
Number of subjects: 60
Study: 25887959

Group type: EXPERIMENTAL
Intervention: Care Programme for the Last Days of Life
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 0
Study: 23360528

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Betadine) soaked surgical gauze
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline soaked surgical gauze
Number of subjects: 49
Study: 21366694

Group type: EXPERIMENTAL
Intervention: Bortezomib plus melphalan-prednisone (VMP)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 682
Study: 19681938

Group type: EXPERIMENTAL
Intervention: Inlay bone grafting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Onlay bone grafting
Number of subjects: 20
Study: 17135457

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 64 mmol/day
Number of subjects: 0
Study: 15520986

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (intramuscular administration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (able-bodied subjects)
Number of subjects: 80
Study: 15086492

Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-African Americans
Number of subjects: 0
Study: 10908985

Group type: EXPERIMENTAL
Intervention: Mucomyst (NAC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9316363

Group type: EXPERIMENTAL
Intervention: Coconut and coconut oil consumption
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 8418313

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by standard therapy with surgery and/or radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus fluorouracil (5-FU) followed by radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative cisplatin plus 5-FU prior to radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical modulation of 5-FU with leucovorin and biologic response modifiers such as interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study: 3080575

Group type: EXPERIMENTAL
Intervention: Ibuprofen (25 mg/kg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin (2 mg/kg/day)
Number of subjects: 8
Study: 2682120

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg over 15 minutes)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31653801

Group type: EXPERIMENTAL
Intervention: Dominant elbow flexors training (EFlex)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dominant leg press training (LP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 30847474

Group type: EXPERIMENTAL
Intervention: 100 mg maintenance dose starting at Week 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg maintenance dose for early nonresponders <80 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg maintenance dose for early nonresponders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early responders
Number of subjects: 0
Study: 28100440

Group type: EXPERIMENTAL
Intervention: Web Behavior Change Program for Activity (Web‐BCPA) in combination with multimodal rehabilitation (MMR)
Number of subjects: 19
Study: 26286532

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (0, 6, 12, or 18 visits)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Post-treatment predictor models
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Post-treatment pain alone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pre-treatment predictor models
Number of subjects: 400

Group type: COMPARATOR
Intervention: Light-massage control (at remaining visits)
Number of subjects: 400
Study: 23464382

Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine episiotomy
Number of subjects: 0
Study: 21127322

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell infusion (BMC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: BMC group
Number of subjects: 101
Study: 19661218

Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CD)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Acetate dialysate (AD)
Number of subjects: 142
Study: 17439763

Group type: EXPERIMENTAL
Intervention: Hyperthermia (HT) combined with radiation therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study: 14634864

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 90 mg/m(2)/day for 42 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 56
Study: 11457531

Group type: EXPERIMENTAL
Intervention: Cholecystokinin‐tetrapeptide (CCK‐4) administered intravenously
Number of subjects: 0
Study: 9631379

Group type: EXPERIMENTAL
Intervention: diclofenac (together with diazepam)
Number of subjects: 206

Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: NSAID (non-steroidal anti-inflammatory drugs)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 206
Study: 8004292

Group type: EXPERIMENTAL
Intervention: 0.10 ppm ozone in filtered air (FA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.25 ppm ozone in filtered air (FA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.40 ppm ozone in filtered air (FA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Filtered air (FA) alone
Number of subjects: 21
Study: 2591089

Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion applied twice daily for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated forearm)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion
Number of subjects: 16
Study: 1218336

Group type: EXPERIMENTAL
Intervention: 125I fibrinogen test
Number of subjects: 72

Group type: COMPARATOR
Intervention: Venography
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Comparison of both techniques
Number of subjects: 72
Study: 31167027

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship programme (ASP) with an appointed antibiotic advisor (AA)
Number of subjects: 920
Study: 27736011

Group type: EXPERIMENTAL
Intervention: modified papilla preservation technique with titanium-reinforced expanded-polytetrafluoroethylene (ePTFE) membranes (MPPT Tit, N = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: access flap with expanded-PTFE membranes (Flap-ePTFE, N = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: access flap alone (Flap, N = 15)
Number of subjects: 45
Study: 26066384

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg intravenous
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 23497021

Group type: EXPERIMENTAL
Intervention: BiPAP S/T with AVAPS
Number of subjects: 22

Group type: COMPARATOR
Intervention: BiPAP S/T
Number of subjects: 22
Study: 21576560

Group type: EXPERIMENTAL
Intervention: ESS with a computer‐assisted surgery system
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ESS without a computer‐assisted surgery system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control day (nonsurgical day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ESS (all conditions)
Number of subjects: 15
Study: 19164621

Group type: EXPERIMENTAL
Intervention: Airtraq optical laryngoscope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study: 16765179

Group type: EXPERIMENTAL
Intervention: alfuzosin 10 mg daily + tadalafil 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: alfuzosin 10 mg daily + placebo
Number of subjects: 18
Study: 15600378

Group type: EXPERIMENTAL
Intervention: Venlafaxine (SNRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study: 11903327

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering interventions in diabetic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood pressure lowering among non-hypertensive individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different classes of drug for blood pressure lowering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADVANCE trial (Action in Diabetes and Vascular Disease)
Number of subjects: 0
Study: 9684433

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Diclofenac 75 mg b.i.d.
Number of subjects: 122
Study: 7804515

Group type: EXPERIMENTAL
Intervention: Urapidil (60 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3408928

Group type: EXPERIMENTAL
Intervention: Carbocisteine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Debrisoquine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal control population
Number of subjects: 74
Study: 31044510

Group type: EXPERIMENTAL
Intervention: Immediate implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Number of subjects: 0
Study: 28467771

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Baseline CTC counts
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduction of CTC enumeration after two cycles of chemotherapy
Number of subjects: 80
Study: 26977135

Group type: EXPERIMENTAL
Intervention: Usual homecare plus five additional nursing interventions at 48 and 72 hours and at 7, 14, and 21 days after discharge
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual homecare
Number of subjects: 103
Study: 24934732

Group type: EXPERIMENTAL
Intervention: LESS‐DN
Number of subjects: 100

Group type: COMPARATOR
Intervention: LDN
Number of subjects: 100
Study: 22250852

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 130
Study: 20073218

Group type: EXPERIMENTAL
Intervention: Wuhu Decoction (WHD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (fluticasone propionate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal control (10 healthy infants)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (WHD and control)
Number of subjects: 60
Study: 17536942

Group type: EXPERIMENTAL
Intervention: Dual Focus Schema Therapy (DFST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 12 Step Facilitation Therapy (12FT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both therapies (DFST and 12FT)
Number of subjects: 30
Study: 15646222

Group type: EXPERIMENTAL
Intervention: Buffered artificial saliva for three weeks followed by APF gel application for four minutes and immersion in artificial saliva for another three weeks.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buffered artificial saliva for three weeks without APF gel application.
Number of subjects: 10
Study: 11704618

Group type: EXPERIMENTAL
Intervention: Vodka mixed with juice (average peak blood‐alcohol level to 0.045%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Juice only (placebo condition)
Number of subjects: 12
Study: 9972339

Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (dorzolamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers and miotics
Number of subjects: 0
Study: 7832024

Group type: EXPERIMENTAL
Intervention: Leadership group (n = 79)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Nonleadership group (n = 124)
Number of subjects: 203
Study: 3134314

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on the upper arm
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on the chest
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on the pelvis
Number of subjects: 56
Study: 29486626

Group type: EXPERIMENTAL
Intervention: Reduced diagnosis threat (DT) condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis threat (DT) condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0